Journal of Nanomedicine & Nanotechnology

Total characterization of ITRI-IOP USPIO nanoparticles as MRI contrast agent

2^nd International Conference on Nanotek and Expo

December 3-5, 2012 DoubleTree by Hilton Philadelphia Center City, USA

Shuimei Wang, Wen-Yuan Hsieh, Shen-Chuan Lo, Chiu-Hun Su and Lien-Tai Chen

Scientific Tracks Abstracts: J Nanomed Nanotechol

Abstract:

ITRI-IOP, a new class of USPIO (Ultrasmall Superparamagnetic Iron Oxide) developed at ITRI (Industrial Technology Research Institute), comprised of iron oxide nanoparticles coated with a monolayer of PEG (polyethylene glycol). The IOP nanoparticles were fully characterized using in-house Nano/Micro instruments at NTRC (Nano Technology Research Center) to study particle sizes, morphology, surface property, and chemical composition. The analytical instruments employed include: TEM (transmission electron microscopy), SEM (scanning electron microscope), AFM (atomic force microscopy), AF4 (asymmetrical flow field-flow fractionation) coupled with SEC (size-exclusion chromatography), DLS (dynamic light scattering) and zeta potential, LC-MS (liquid chromatography?mass spectrometry), MALDI-MS (matrix-assisted laser desorption/ionization), and Multinuclear NMR (nuclear magnetic resonance) spectroscopy. The ITRI-IOP exhibited particle sizes about 10-15 nm analyzed by TEM, while 50-70 nm by DSL. To further investigate, IOP particle suspension was separated using AF4 first, and then followed by DSL. The IOP suspension showed particle size distribution ranging from 15 nm to 150 nm, with core particle sizes around 15-20 nm, consistent with what measured by TEM. A few larger particles (up to 150 nm) suggested the presence of minor particle aggregation. IOP also exhibited surface charge measured by Zeta potential. The presence of PEG and Si-coupling were confirmed by Multinuclear NMR. The new ITRI-IOP, which showed high magnetic relaxivity r2 value, good biocompatibility and low cytotoxicity, could be applied as contrast agent in MRI (magnetic resonance imaging)

Biography :

Shuimei Wang currently is assisting Dr. Chen, General Director of Nano Technology Research Center of Industrial Technology Research Institute in Taiwan. Prior returning to Taiwan in 2012, Dr. Wang worked in US for many years covering several disciplines, ranging from cancer research at NCI/ NIH, drug development at Wyeth/Pfizer Pharmaceuticals, analytical development at GAF/ISP/Ashland, cellulose/printing/packaging at International Paper, and anti-counterfeiting at BEP. Dr. Wang received BS in Chemistry from National Tsing Hua University and Ph.D. in Chemistry from Kent State University. She also studied ?Clinical Pharmacology? and ?Clinical Research? at NIH Clinical Center, and ?Project Management? at SUNY-Rockland